Celltrion reported on Wednesday that its subcutaneous injection treatment, Zymfentra (marketed as Remsima SC in the U.S.), has seen a rapid increase in prescriptions across the U.S. this year, marking a significant growth phase for the product.
In January, Zymfentra achieved its highest monthly prescription volume to date, with a more than threefold (213%) increase compared to the same period last year. This represents the steepest growth since the product’s launch.
January’s prescription volume not only surpassed that of the same month last year but also exceeded the total prescriptions for the entire first quarter of the previous year. This trend indicates Zymfentra’s rapidly growing adoption in the U.S. healthcare market.
The growth trend for Zymfentra is further substantiated by actual market demand. Celltrion reported that as of February, the shipment volume of Zymfentra to U.S. wholesalers and retailers has increased by more than 3.5 times compared to the same period last year.
Since Zymfentra’s launch in March 2024, Celltrion has been actively engaging with autoimmune disease specialists throughout the United States.
Notably, Celltrion Group executives, including Chairman Seo Jung-jin, and sales representatives from the U.S. branch have been meeting directly with key healthcare professionals. These meetings aim to highlight Zymfentra’s clinical value and its advantages as a treatment option.
The rapid inclusion of Zymfentra in insurance formularies that allow patient reimbursement has also significantly boosted sales. Additionally, both online and offline advertising campaigns targeting patients have positively impacted the expansion of Zymfentra prescriptions.
Given these market trends, Celltrion anticipates further acceleration in the growth of Zymfentra prescriptions and sales in the coming months.
A Celltrion spokesperson stated that Zymfentra’s prescription volume more than tripled in January compared to last year, and February’s shipment data confirms that this growth is driven by genuine hospital demand. Its 3P strategy, which targets healthcare professionals, insurance companies, and patients, is now yielding concrete results.
